AtaiBeckley (ATAI) Short term Debt (2021 - 2026)

AtaiBeckley (ATAI) posted quarterly Short term Debt of $310000.0 for Q1 2026, up 14.39% quarter-over-quarter from $271000.0 in Q4 2025.

Analysis

AtaiBeckley (ATAI) Short term Debt (2021 - 2026) Analysis & Trends

AtaiBeckley's Short term Debt history runs 3 years deep, the most recent figure standing at $310000.0 for Q1 2026.

In Q1 2026, Short term Debt changed N/A year-over-year to $310000.0; the TTM figure through Mar 2026 stood at $310000.0 (changed N/A YoY), while the FY2025 annual figure was $271000.0, down 95.75% from the prior year.
Short term Debt for Q1 2026 stood at $310000.0, up from $271000.0 in the prior quarter.
Over five years, Short term Debt peaked at $161.5 million in Q3 2022 and troughed at $38000.0 in Q3 2021.
A 5-year average of $30.8 million and a median of $275000.0 in 2023 frame the typical range for Short term Debt.
Peak annual rise in Short term Debt reached 95.75% in 2025, while the deepest fall reached 95.75% in 2025.
AtaiBeckley's Short term Debt stood at $6.4 million in 2024, then plunged by 95.75% to $271000.0 in 2025, then grew by 14.39% to $310000.0 in 2026.
Business Quant data shows ATAI's Short term Debt at $310000.0 in Q1 2026, $271000.0 in Q4 2025, and $6.4 million in Q4 2024.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	AtaiBeckley	1.61 Bn	1.61 Bn	-

Historic Data

Download Data